

December 30, 2009

Diane Manninen, PhD  
Battelle CPHRE  
1100 Dexter Avenue North  
Suite 400  
Seattle, WA 98109

Dear Dr. Manninen:

As Chair of the Battelle/CPHRE Institutional Review Board (IRB) I have reviewed the continuing review and modifications submission dated 12/29/2009 for the study entitled "Estimating the Capacity for National & State-level Colorectal Cancer Screening through a Survey of Endoscopic Capacity" (FG929902-01) and grant expedited approval to continue with the study and implement the changes. The study is minimal risk. The changes which include increasing the number of facilities, adding questions to the survey and modifying questions do not affect the risk/benefits ratio.

As with all Battelle/CPHRE studies, this study will be subject to continuing review again next year. The current approval expires 12/29/2010. We will send you notification at the appropriate time. In the meantime, should any additional changes occur in your protocol or questionnaire, please inform the IRB and submit the changes for review. Similarly, the IRB needs to be notified in the event of any injury or unexpected outcome arising from this study.

Sincerely,



Margaret R. Pennybacker, PhD  
IRB Chair

cc: Brigette Brevard  
Contracts  
Jan Jaeger

**Battelle/Centers for Public Health Research and Evaluation**

100 Capitola Drive, Suite 200

Durham, NC 27713

Federal-wide Assurance No. FWA00004696 (IRB No. 284)

**INSTITUTIONAL REVIEW BOARD NOTICE OF APPROVAL**

PROJECT DIRECTOR: Diane Manninen

PROJECT TITLE: Estimating the Capacity for National & State-level Colorectal Cancer Screening through a Survey of Endoscopic Capacity

CLIENT: CDC

PROTOCOL DATE: 12/29/09

BATTELLE PROJECT CODE: FG929902-01

or PROPOSAL NUMBER:      (if preaward)

NATURE OF REVIEW: (check one)

<input type="checkbox"/>
<input checked="" type="checkbox"/>
<input type="checkbox"/>

FULL MEETING DATE: \_\_\_\_\_

EXPEDITED (specify reason): minimal risk; no change to risk/benefits

EXEMPT (specify reason): \_\_\_\_\_

TYPE OF APPROVAL: (check one)

<input type="checkbox"/>
<input type="checkbox"/>
<input type="checkbox"/>
<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>

PRELIMINARY. SCHEDULE NEXT REVIEW PRIOR TO INVOLVEMENT OF HUMAN SUBJECTS.

PRETEST/PILOT TEST. SCHEDULE NEXT REVIEW PRIOR TO FULL IMPLEMENTATION.

FULL IMPLEMENTATION.

RENEWAL/CONTINUING REVIEW.

AMENDMENT DATED 12/29/09

**Please note the following requirements:**

**PROBLEMS OR ADVERSE REACTIONS:** If any problems in treatment of human subjects or unexpected adverse reactions occur as a result of this study, you must notify the IRB Chairperson immediately, then complete an Adverse Event/Incident Report and forward it to the CPHRE IRB Administrator.

**CHANGES IN PROTOCOL:** If there are any changes in procedures or study protocol, you must notify the IRB Chairperson and submit the revisions for review before they are implemented.

**RENEWAL:** You are required to apply for renewal of approval at least annually for as long as the study is active unless the Board finds it necessary to require more frequent reviews. Your next continuing review date should be on or before 12/29/10.

Margaret Pennybacker                      12/30/09  
IRB Chairperson                                      Date

Margaret R. Pennybacker, PhD  
Print or Type Name

X Copy of approved Informed Consent on file.

cc: Project Director  
IRB Administrator